Workflow
速递|刚刚,礼来替尔泊肽又一适应症联合胰岛素疗法在华获批

Core Viewpoint - The approval of Eli Lilly's GLP-1 drug Tirzepatide (brand name: Mounjaro) by the National Medical Products Administration of China for a new indication in treating adult Type 2 Diabetes Mellitus (T2DM) patients highlights its potential to improve blood sugar control when used in conjunction with insulin and lifestyle modifications [1][3]. Group 1 - The new indication for Tirzepatide aims to provide a safe and effective treatment option for T2DM patients who have a long disease course and have not achieved adequate blood sugar control despite insulin therapy [3]. - Tirzepatide has demonstrated significant advantages in blood sugar control, weight reduction, and metabolic improvement since its market launch [3]. Group 2 - The "GLP-1 Club" has established a network of hundreds of professionals, creating a premier platform for industry insights related to the GLP-1 sector [5]. - The club offers various resources, including academic promotions and consulting services, to support the GLP-1 community [6].